Grace Therapeutics, INC. (GRCE) — 10-Q Filings

All 10-Q filings from Grace Therapeutics, INC.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (5)

Grace Therapeutics' Net Loss Widens to $5.2M Amid R&D Push — Aug 12, 2025 Risk: high
Grace Therapeutics, Inc. (GRCE) reported no revenue for the quarter ended June 30, 2025, consistent with its status as a clinical-stage pharmaceutical company.
Grace Therapeutics Files Q3 2024 10-Q — Feb 13, 2025 Risk: low
Grace Therapeutics, Inc. filed its 10-Q report for the quarterly period ended December 31, 2024. The company, formerly known as Acasti Pharma Inc., is incorpora
Grace Therapeutics Files 10-Q for Q2 2024 — Nov 13, 2024 Risk: low
Grace Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Acasti Pharma Inc., is incorporated in Delaware
Acasti Pharma 10-Q: Financials & Warrant Adjustments — Aug 9, 2024 Risk: medium
Acasti Pharma Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position and operations, including details on commo
Acasti Pharma Inc. Files 10-Q for Period Ending December 31, 2023 — Feb 12, 2024 Risk: low
Acasti Pharma Inc. (GRCE) filed a Quarterly Report (10-Q) with the SEC on February 12, 2024. Acasti Pharma Inc. filed a 10-Q report for the period ending Decemb

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX